Polpharma looks to challenge Takeda’s Entyvio in IBD

2024-02-21

临床3期上市批准临床结果财报生物类似药

Polpharma looks to challenge Takeda’s Entyvio in IBD

Preview

来源: Pharmaceutical Technology

Takeda’s Entyvio generated Y936.1bn ($6.2bn) in the first nine months of 2023, as per Takeda’s Q3 financials. Image Credit: Marian Weyo / Shutterstock.

Netherland-based Polpharma Biologics has released topline results from the Phase III trial of its biosimilar candidate PB016, showing that the biosimilar is non-inferior to its reference biologic, Takeda Pharmaceuticals’ Entyvio (vedolizumab).

Entyvio is an α4β7 integrin targeting monoclonal antibody that helps in reducing gastrointestinal inflammation. It was approved to treat inflammatory bowel disease (IBD), namely ulcerative colitis (UC) and Crohn’s disease, by the US Food and Drug Administration (FDA) in 2014. The therapy generated Y936.1bn ($6.2bn) in the first nine months of 2023, as per Takeda’s Q3 financials.

The Phase III trial evaluated the efficacy, safety and immunogenicity of PB016 in comparison with Entyvio in 120 healthy participants. PB016 was comparable to Entyvio across pharmacokinetic and pharmacodynamic parameters. Furthermore, there were no immunogenicity or safety imbalances between the two therapies.

Polpharma is also investigating PB016 in a Phase III trial (NCT05771155) against Entyvio in UC patients. The study is expected to enrol 750 participants and will conclude in September 2025, as per ClinicalTrials.gov.

The IBD market is predicted to grow in the next decade, and GlobalData estimates that the Crohn’s and UC markets will be worth approximately $14.9bn and $11.2bn by 2032. The global sales of Entyvio are projected to reach $7.9bn by 2029, as per GlobalData’s market analysis.

See Also:Modakafusp alfa by Takeda Pharmaceutical for Metastatic Melanoma: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

GlobalData is the parent company of Pharmaceutical Technology.

Takeda has also invested in sustaining and increasing revenue generated by Entyvio. The company developed a subcutaneous formulation of the monoclonal antibody, which was approved by the US FDA as a maintenance therapy to treat moderately to severely active UC in adults following induction therapy with intravenous Entyvio in September 2023.

Another biosimilar developed by Polpharma is Biogen’s Tysabri (natalizumab) biosimilar, Tyruko. The biosimilar is licensed to Sandoz Sandoz, which bears responsibility for distribution and commercialisation. Tyruko was approved by the FDA for all multiple sclerosis (MS) settings where Tysabri is currently used, including relapsing-remitting MS, clinically isolated syndrome (CIS), and active secondary progressive disease, in addition to Crohn’s disease in August 2023.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构